Compare HFFG & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HFFG | QNCX |
|---|---|---|
| Founded | 1997 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Distributors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 124.7M | 139.2M |
| IPO Year | N/A | 2019 |
| Metric | HFFG | QNCX |
|---|---|---|
| Price | $2.60 | $4.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.75 |
| AVG Volume (30 Days) | 77.9K | ★ 1.1M |
| Earning Date | 11-10-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,225,541,000.00 | N/A |
| Revenue This Year | $4.36 | N/A |
| Revenue Next Year | $3.35 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 4.10 | N/A |
| 52 Week Low | $1.70 | $0.72 |
| 52 Week High | $4.93 | $4.55 |
| Indicator | HFFG | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 55.07 | 75.56 |
| Support Level | $2.54 | $3.74 |
| Resistance Level | $2.79 | $4.30 |
| Average True Range (ATR) | 0.12 | 0.46 |
| MACD | 0.02 | 0.10 |
| Stochastic Oscillator | 55.67 | 86.67 |
HF Foods Group Inc is an Asian food service distributor that markets and distributes fresh produce, seafood, frozen and dry food, and non-food products to Asian restaurants and other food service customers throughout the United States. The company's business consists of one operating segment; HF Group, which operates solely in the United States. The company's customer base consists of Chinese and Asian restaurants, and it provides sales and service support to customers who mainly converse in Mandarin or Chinese dialects.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.